Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Thiotepa, Busulfan and Fludarabine Conditioning Regimen in Adult Patients Undergoing Allogeneic Stem Cell Transplantation for Lymphoid Malignancies. a Study on Behalf of Geth-TC

Marta Peña, Annalisa Paviglianiti, Maria Jesús Pascual, Beatriz Herruzo, Carlos Solano, Ana Benzaquen, Maria Queralt Salas, Montserrat Rovira, Agustin Nieto, Ignacio Español, Adolfo Jesús Sáez Marín, Leyre Bento De Miguel, Anna Maria Sureda Balari, Alberto Mussetti

Blood (2023) 142 (Supplement 1): 2171.

https://doi.org/10.1182/blood-2023-180683

Published: 2023

Journal Articles

Long Term Outcomes and Renal Response Following Autologous Stem Cell Transplantation for Light Chain Deposition Disease:a Retrospective Study on Behalf of the Cmwp of the EBMT

Blood (2023) 142 (Supplement 1): 3403.

https://doi.org/10.1182/blood-2023-184367

Published: 2023

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients: The Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC)

Blood (2023) 142 (Supplement 1): 4910.

https://doi.org/10.1182/blood-2023-174115

Published: 2023

Journal Articles

Graft-Versus-Host Disease (GvHD) and Steroid-Refractory GvHD after Allogeneic Hematopoietic Stem Cell Transplantation: A Large Real-World EBMT-Based Epidemiology and Treatment Pattern Study

Blood (2023) 142 (Supplement 1): 7016.

https://doi.org/10.1182/blood-2023-177866

Published: 2023

Journal Articles

Impact of Post-Transplant Cyclophosphamide (PTCY)-Based Prophylaxis in Matched Sibling Donor Allo-HCT for Patients with Myelodysplastic Syndrome: A Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Blood (2023) 142 (Supplement 1): 4938.

https://doi.org/10.1182/blood-2023-174609

Published: 2023

Journal Articles

Comparing Older Matched Related to Younger Matched Unrelated Donors in Acute Myeloid Leukemia in Remission Using Post-Transplant Cyclophosphamide

Simona Piemontese, Myriam Labopin, Goda Choi, Annoek E.C. Broers, Ellen Meijer, Gwendolyn Van Gorkom, Montserrat Rovira, Maria Jesús Pascual, Simona Sica, Jan Vydra, Aleksander Kulagin, Alexandros Spyridonidis, Arnon Nagler, Ali Bazarbachi, Bipin N. Savani, Eolia Brissot, Jaime Sanz, Mohamad Mohty, Fabio Ciceri

Blood (2023) 142 (Supplement 1): 1043.

https://doi.org/10.1182/blood-2023-182923

Published: 2023

Journal Articles

Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Large B-Cell Lymphomas in the CART Era

Blood (2022) 140 (Supplement 1): 665–667.

https://doi.org/10.1182/blood-2022-160000

Published: 2022

Journal Articles

Post-Transplant Cyclophosphamide after HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of Geth-TC

Blood (2021) 138 (Supplement 1): 3913.

https://doi.org/10.1182/blood-2021-150835

Published: 2021

Journal Articles

Post-Transplant Cyclophosphamide for Gvhd Prophylaxis in Matched Unrelated Donor Transplantation Compared to ATG-Based Prophylaxis

Rebeca Bailén, MD, Mi Kwon, MD, Maria Jesus Pascual-Cascon, Anna Torrent, Christelle M Ferra, Jaime Sanz, MD PhD, Alberto Doblas-Marquez, Olga Benítez, MD, Jose Luis Piñana Sanchez, Gillen Oarbeascoa, MD, Nieves Dorado, MD, Muñoz Cristina, Carolina Martínez-Laperche, Javier Anguita, MD PhD, Ismael Buño, PhD, José Luis Díez-Martín, MD PhD

Blood (2019) 134 (Supplement_1): 3285.

https://doi.org/10.1182/blood-2019-124849

Published: 2019

Journal Articles

Post-Transplant Cyclophosphamide Versus MTX-CSA As Gvhd Prophylaxis in HLA-Identical Sibling HSCT

Rebeca Bailén, MD, Maria-Jesús Pascual, MD, Pascual Balsalobre, PhD, Anabel Gallardo-Morillo, MD, Abel García-Sola, MD, David Serrano, MD, Javier Anguita, MD PhD, Ismael Buño, PhD, Nieves Dorado Herrero, MD, Laura Solán, PhD, Jose Díez-Martín, MD PhD, Mi Kwon

Blood (2018) 132 (Supplement 1): 3394.

https://doi.org/10.1182/blood-2018-99-110551

Published: 2018

Journal Articles

The Management of Relapsed Hodgkin´s Lymphoma after Haploidentical Stem Cell Transplantation: Donnor Lymphocyte Infusion and Brentuximab Vedotin

Alejandro Contento-Gonzalo, MD, Irene Sánchez-Bazán, MD, Daniel Barrios-Decoud, Maria Magdalena Alcalá-Peña, Maria Jesus Pascual-Cascon, Ana Isabel Heiniger, MD

Blood (2017) 130 (Supplement 1): 5502.

https://doi.org/10.1182/blood.V130.Suppl_1.5502.5502

Published: 2017

Journal Articles

Validation of Scores Predicting Non-Relapse Mortality in Patients with Myelodysplastic Syndrome: A Study on 1276 Patients on Behalf the Chronic Malignancies Working Party of the EBMT

Blood (2017) 130 (Supplement 1): 2028.

https://doi.org/10.1182/blood.V130.Suppl_1.2028.2028

Published: 2017

Journal Articles

An EBMT Analysis of Matched Sibling, Mismatched Family or Matched Unrelated Donors for Allogeneic Stem Cell Transplants in MDS

Blood (2017) 130 (Supplement 1): 4593.

https://doi.org/10.1182/blood.V130.Suppl_1.4593.4593

Published: 2017

Journal Articles

Impact of In Vivo T-Cell Depletion in Patients with Myelodysplastic Syndromes Undergoing Allogeneic Hematopoietic Stem Cell Transplant: A Registry Study from the Chronic Malignancies Working Party of the EBMT

Blood (2017) 130 (Supplement 1): 520.

https://doi.org/10.1182/blood.V130.Suppl_1.520.520

Published: 2017

Journal Articles

Myeloablative Conditioning Haploidentical Stem Cell Transplantation (MAC-HAPLO) with Post-Transplant Cyclophosphamide (PTCy) As GvHD Prophylaxis in High Risk Leukemias/Myelosdysplastic Syndromes (MDS): Geth Experience

Blood (2016) 128 (22): 4690.

https://doi.org/10.1182/blood.V128.22.4690.4690

Published: 2016

Journal Articles

Influence of CD34+ and CD3+ Graft Content on Gvhd Development after Haploidentical Allogeneic Transplantation with Post-Transplant Cyclophosphamide

Mariana Bastos-Oreiro, MD, Pascual Balsalobre, PhD, Diana Champ, MD, Juan Churruca, MD, Maria Jesus Pascual, MD, Pilar Herrera, MD, Leyre Bento, MD, Jose Luis Piñana, MD, Santiago Jimenez, MD, Karem Humala, MD, Pau Montesinos, MD, Inmaculada Heras, MD, Almudena Iglesias, MD, Ana Perez-Corral, MD, Cristina Pascual, MD, Carolina Martinez-Laperche, PhD, Mi Kwon, MD, Jorge Gayoso, MD, Jose L. Diez-Martin, MD PhD

Blood (2015) 126 (23): 3131.

https://doi.org/10.1182/blood.V126.23.3131.3131

Published: 2015

Journal Articles

Haploidentical Stem Cell Transplantation (HAPLO-HSCT) With Reduced Intensity Conditioning (RIC) Regimens and High Dose Cylophosphamide Post-Transplant (HD-CY) As Gvhd Prophylaxis In Patients With Relapsed Or Refractory Hodgkin´s Disease: Multicentric Spanish Experience

Jorge Gayoso, MD, Pascual Balsalobre, MSc, Cristina Castilla-Llorente, MD, María Jesús Pascual, MD, Mi Kwon, MD, David Serrano, MD, Dolores Caballero, MD, PhD, Jose Antonio Pérez-Simón, Arancha Bermudez, MD, Carmen Martínez, MD, Cristina Pascual, MD, Inmaculada Heras, Carlos Solano, Angela Figuera, MD, Antonia Sampol, MD, PhD, Christelle Ferra, MD, Pilar Herrera, Ismael Buno, PhD, Jose Luis Diez-Martin, MD, PhD

Blood (2013) 122 (21): 3406.

https://doi.org/10.1182/blood.V122.21.3406.3406

Published: 2013

Journal Articles

Haploidentical Stem Cell Transplantation (HAPLO-HSCT) With High Dose Cyclophosphamide Post-Transplant (HD-CY) As Gvhd Prophylaxis In High Risk Hematologic Malignancies: Multicentric Spanish Experience

Blood (2013) 122 (21): 2173.

https://doi.org/10.1182/blood.V122.21.2173.2173

Published: 2013

Journal Articles

Haploidentical Transplantation (HAPLO) with Post-Transplant High-Dose Cyclophosphamide for Graft Vs Host Disease (GVHD) Prevention in the Treatment of High Risk Hematological Neoplasms

Jorge Gayoso, MD, Mi Kwon, MD, David Serrano, MD, Pascual Balsalobre, MSc, Javier Anguita, MD, Cristina Pascual, MD, Ana Pérez-Corral, MD, Ismael Buno, PhD, Carolina Martinez-Laperche, PhD, Cristina Castilla-Llorente, Inmaculada Heras, Maria Jesus Pascual, Dolores Caballero, MD, Jose Luis Diez-Martin, PhD

Blood (2012) 120 (21): 4545.

https://doi.org/10.1182/blood.V120.21.4545.4545

Published: 2012

Journal Articles

Outcome of Second Allogeneic SCT Following Relapse of Hematological Malignancies After a First Allogeneic SCT

Blood (2011) 118 (21): 3056.

https://doi.org/10.1182/blood.V118.21.3056.3056

Published: 2011

NARROW

Thiotepa, Busulfan and Fludarabine Conditioning Regimen in Adult Patients Undergoing Allogeneic Stem Cell Transplantation for Lymphoid Malignancies. a Study on Behalf of Geth-TC

Long Term Outcomes and Renal Response Following Autologous Stem Cell Transplantation for Light Chain Deposition Disease:a Retrospective Study on Behalf of the Cmwp of the EBMT

Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients: The Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC)

Graft-Versus-Host Disease (GvHD) and Steroid-Refractory GvHD after Allogeneic Hematopoietic Stem Cell Transplantation: A Large Real-World EBMT-Based Epidemiology and Treatment Pattern Study

Impact of Post-Transplant Cyclophosphamide (PTCY)-Based Prophylaxis in Matched Sibling Donor Allo-HCT for Patients with Myelodysplastic Syndrome: A Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Comparing Older Matched Related to Younger Matched Unrelated Donors in Acute Myeloid Leukemia in Remission Using Post-Transplant Cyclophosphamide

Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Large B-Cell Lymphomas in the CART Era

Post-Transplant Cyclophosphamide after HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of Geth-TC

Post-Transplant Cyclophosphamide for Gvhd Prophylaxis in Matched Unrelated Donor Transplantation Compared to ATG-Based Prophylaxis

Post-Transplant Cyclophosphamide Versus MTX-CSA As Gvhd Prophylaxis in HLA-Identical Sibling HSCT

The Management of Relapsed Hodgkin´s Lymphoma after Haploidentical Stem Cell Transplantation: Donnor Lymphocyte Infusion and Brentuximab Vedotin

Validation of Scores Predicting Non-Relapse Mortality in Patients with Myelodysplastic Syndrome: A Study on 1276 Patients on Behalf the Chronic Malignancies Working Party of the EBMT

An EBMT Analysis of Matched Sibling, Mismatched Family or Matched Unrelated Donors for Allogeneic Stem Cell Transplants in MDS

Impact of In Vivo T-Cell Depletion in Patients with Myelodysplastic Syndromes Undergoing Allogeneic Hematopoietic Stem Cell Transplant: A Registry Study from the Chronic Malignancies Working Party of the EBMT

Myeloablative Conditioning Haploidentical Stem Cell Transplantation (MAC-HAPLO) with Post-Transplant Cyclophosphamide (PTCy) As GvHD Prophylaxis in High Risk Leukemias/Myelosdysplastic Syndromes (MDS): Geth Experience

Influence of CD34+ and CD3+ Graft Content on Gvhd Development after Haploidentical Allogeneic Transplantation with Post-Transplant Cyclophosphamide

Haploidentical Stem Cell Transplantation (HAPLO-HSCT) With Reduced Intensity Conditioning (RIC) Regimens and High Dose Cylophosphamide Post-Transplant (HD-CY) As Gvhd Prophylaxis In Patients With Relapsed Or Refractory Hodgkin´s Disease: Multicentric Spanish Experience

Haploidentical Stem Cell Transplantation (HAPLO-HSCT) With High Dose Cyclophosphamide Post-Transplant (HD-CY) As Gvhd Prophylaxis In High Risk Hematologic Malignancies: Multicentric Spanish Experience

Haploidentical Transplantation (HAPLO) with Post-Transplant High-Dose Cyclophosphamide for Graft Vs Host Disease (GVHD) Prevention in the Treatment of High Risk Hematological Neoplasms

Outcome of Second Allogeneic SCT Following Relapse of Hematological Malignancies After a First Allogeneic SCT

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only